Recordati is a well-established international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals with more than 4,300 employees listed on the Italian Stock Exchange since 1984. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, in Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia.
Recordati offers a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized segment dedicated to treatments for rare diseases. An efficient field force of medical representatives and orphan drug representatives promotes its products in about 150 markets.
Worldwide
Headcount4,300
HeadquartersVia M. Civitali 1, 20148 Milano – Italy
Line item in (eur) | 01.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
---|---|---|---|---|---|---|
Assets | N/A | 2,711,654,000.00 | N/A | 2,816,199,000.00 | N/A | 3,998,823,000.00 |
Noncurrent Assets | N/A | 1,938,703,000.00 | N/A | 1,966,098,000.00 | N/A | 2,812,736,000.00 |
Goodwill | N/A | 562,116,000.00 | N/A | 553,209,000.00 | N/A | 780,057,000.00 |
Intangible Assets Other Than Goodwill | N/A | 1,115,811,000.00 | N/A | 1,138,786,000.00 | N/A | 1,758,173,000.00 |
Deferred Tax Assets | N/A | 75,084,000.00 | N/A | 75,922,000.00 | N/A | 76,895,000.00 |
Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | N/A | 45,581,000.00 | N/A | 34,124,000.00 | N/A | 28,871,000.00 |
Other Noncurrent Assets | N/A | 6,861,000.00 | N/A | 32,937,000.00 | N/A | 9,556,000.00 |
Current Assets | N/A | 772,951,000.00 | N/A | 850,101,000.00 | N/A | 1,173,617,000.00 |
Current Trade Receivables | N/A | 268,897,000.00 | N/A | 307,778,000.00 | N/A | 361,898,000.00 |
Other Current Receivables | N/A | 47,291,000.00 | N/A | 44,880,000.00 | N/A | 63,915,000.00 |
Cash and cash equivalents | 187,923,000.00 | 188,230,000.00 | 188,230,000.00 | 244,578,000.00 | 244,578,000.00 | 284,734,000.00 |
Noncurrent Assets Or Disposal Groups Classified As Held For Distribution To Owners | N/A | N/A | N/A | 0.00 | N/A | 12,470,000.00 |
Other Current Assets | N/A | 10,245,000.00 | N/A | 12,984,000.00 | N/A | 15,387,000.00 |
Equity And Liabilities | N/A | 2,711,654,000.00 | N/A | 2,816,199,000.00 | N/A | 3,998,823,000.00 |
Equity | 1,198,811,000.00 | 1,276,260,000.00 | N/A | 1,381,625,000.00 | N/A | 1,546,248,000.00 |
Issued Capital | N/A | 26,141,000.00 | N/A | 26,141,000.00 | N/A | 26,141,000.00 |
Retained Earnings | N/A | 1,151,053,000.00 | N/A | 1,275,962,000.00 | N/A | N/A |
Retained Earnings Profit Loss For Reporting Period | N/A | N/A | N/A | 385,966,000.00 | N/A | 312,336,000.00 |
Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | N/A | 1,275,962,000.00 | N/A | 1,524,099,000.00 |
Share Premium | N/A | 83,719,000.00 | N/A | 83,719,000.00 | N/A | 83,719,000.00 |
Treasury Shares | N/A | 87,516,000.00 | N/A | 126,981,000.00 | N/A | 149,559,000.00 |
Other Reserves | N/A | 70,707,000.00 | N/A | 60,207,000.00 | N/A | 62,260,000.00 |
Equity Attributable To Owners Of Parent | N/A | 1,275,983,000.00 | N/A | 1,381,625,000.00 | N/A | 1,546,248,000.00 |
Noncontrolling Interests | N/A | 277,000.00 | N/A | 0.00 | N/A | 0.00 |
Noncurrent Liabilities | N/A | 856,930,000.00 | N/A | 808,158,000.00 | N/A | 1,528,832,000.00 |
Noncurrent Provisions For Employee Benefits | N/A | 21,174,000.00 | N/A | 21,010,000.00 | N/A | 19,418,000.00 |
Other Noncurrent Payables | N/A | 16,299,000.00 | N/A | 0.00 | N/A | N/A |
Deferred Tax Liabilities | N/A | 41,219,000.00 | N/A | 26,675,000.00 | N/A | 167,865,000.00 |
Current Liabilities | N/A | 578,464,000.00 | N/A | 626,416,000.00 | N/A | 923,743,000.00 |
Current Provisions | N/A | 17,113,000.00 | N/A | 21,396,000.00 | N/A | 16,209,000.00 |
Trade And Other Current Payables To Trade Suppliers | N/A | 132,096,000.00 | N/A | 177,925,000.00 | N/A | 224,703,000.00 |
Other Current Payables | N/A | 95,671,000.00 | N/A | 145,170,000.00 | N/A | 251,136,000.00 |
Current Tax Liabilities Current | N/A | 29,743,000.00 | N/A | 29,543,000.00 | N/A | 33,615,000.00 |
Other Current Financial Liabilities | N/A | 12,567,000.00 | N/A | 8,657,000.00 | N/A | 83,425,000.00 |
Other Current Liabilities | N/A | 11,250,000.00 | N/A | 6,508,000.00 | N/A | 5,740,000.00 |
Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
31.12.2021/ 01.01.2022 |
31.12.2022/ 01.01.2023 |
---|---|---|---|---|
Revenue | 1,448,867,000.00 | 1,580,074,000.00 | 1,580,074,000.00 | 1,853,307,000.00 |
Profit Loss From Operating Activities | 469,016,000.00 | 490,190,000.00 | 490,190,000.00 | 437,326,000.00 |
Profit Loss Before Tax | 455,656,000.00 | 463,349,000.00 | 463,349,000.00 | 401,435,000.00 |
Income Tax Expense Continuing Operations | 100,629,000.00 | 77,383,000.00 | 77,383,000.00 | 89,099,000.00 |
Profit (loss) | 355,027,000.00 | 385,966,000.00 | 385,966,000.00 | 312,336,000.00 |
Profit Loss Attributable To Owners Of Parent | 354,984,000.00 | 385,966,000.00 | 385,966,000.00 | 312,336,000.00 |
Profit Loss Attributable To Noncontrolling Interests | 43,000.00 | 0.00 | 0.00 | 0.00 |
Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 02.01.2021 | 02.01.2022 | 01.01.2023 |
---|---|---|---|---|---|---|
Profit (loss) | N/A | 355,027,000.00 | 385,966,000.00 | N/A | N/A | 312,336,000.00 |
Adjustments For Income Tax Expense | N/A | 100,629,000.00 | 77,383,000.00 | N/A | N/A | 89,101,000.00 |
Adjustments For Decrease Increase In Inventories | N/A | 42,924,000.00 | -17,506,000.00 | N/A | N/A | 65,801,000.00 |
Adjustments For Increase Decrease In Trade Account Payable | N/A | 38,614,000.00 | -46,335,000.00 | N/A | N/A | -25,589,000.00 |
Adjustments For Sharebased Payments | N/A | 4,878,000.00 | 5,082,000.00 | N/A | N/A | 8,251,000.00 |
Other Adjustments For Noncash Items | N/A | 1,997,000.00 | 12,925,000.00 | N/A | N/A | 70,751,000.00 |
Interest Paid Classified As Operating Activities | N/A | -18,699,000.00 | -18,279,000.00 | N/A | N/A | -20,093,000.00 |
Interest Received Classified As Operating Activities | N/A | 463,000.00 | 291,000.00 | N/A | N/A | 1,938,000.00 |
Income Taxes Paid Refund Classified As Operating Activities | N/A | -65,272,000.00 | -91,646,000.00 | N/A | N/A | -89,764,000.00 |
Cash Flows From Used In Operating Activities | N/A | 403,575,000.00 | 491,650,000.00 | N/A | N/A | 461,691,000.00 |
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 66,000.00 | 0.00 | N/A | N/A | N/A |
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | 304,000.00 | N/A | N/A | 673,259,000.00 |
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 161,000.00 | N/A | N/A | 1,156,000.00 |
Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 21,263,000.00 | 21,852,000.00 | N/A | N/A | 23,887,000.00 |
Proceeds From Sales Of Intangible Assets Classified As Investing Activities | N/A | 57,000.00 | 4,000.00 | N/A | N/A | 1,318,000.00 |
Purchase Of Intangible Assets Classified As Investing Activities | N/A | 110,415,000.00 | 65,508,000.00 | N/A | N/A | 72,452,000.00 |
Cash Flows From Used In Investing Activities | N/A | -131,555,000.00 | -87,499,000.00 | N/A | N/A | -767,124,000.00 |
Payments To Acquire Or Redeem Entitys Shares | N/A | 47,871,000.00 | 101,820,000.00 | N/A | N/A | 52,267,000.00 |
Payments Of Lease Liabilities Classified As Financing Activities | N/A | 9,730,000.00 | 9,153,000.00 | N/A | N/A | 10,225,000.00 |
Dividends Paid Classified As Financing Activities | N/A | 212,718,000.00 | 216,742,000.00 | N/A | N/A | 230,602,000.00 |
Cash Flows From Used In Financing Activities | N/A | -264,288,000.00 | -355,943,000.00 | N/A | N/A | 341,277,000.00 |
Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -7,425,000.00 | 7,661,000.00 | N/A | N/A | 4,312,000.00 |
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 7,732,000.00 | 48,208,000.00 | N/A | N/A | 35,844,000.00 |
Cash and cash equivalents | 187,923,000.00 | 188,230,000.00 | 244,578,000.00 | 188,230,000.00 | 244,578,000.00 | 284,734,000.00 |
Please note that some sums might not add up.
IT0003828271
LEI815600FBF92FD3531704
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE MIB
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.